NCT01105598View on ClinicalTrials.gov

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 20, 2010

Primary Completion Date

October 2, 2010

Study Completion Date

October 2, 2010

Conditions
Mild Dyslipidemia
Interventions
DRUG

ETC-1002 or placebo

ETC-1002 (ascending dose), daily for 14 days

DRUG

ETC-1002 or placebo

ETC-1002 (optimized dose), daily for 28 days

DRUG

ETC-1002 or placebo

ETC-1002 (20 mg), daily for 14 days

Trial Locations (1)

49007

Jasper Clinic, Inc., Kalamazoo

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY